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Exploring Meaningful Patient Engagement in
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial
Assessing Benefits and Long-term Effectiveness)
Madelaine Faulkner, MPH,* Jacqueline Alikhaani, Linda Brown, Henry Cruz, Desiree Davidson,
Ken Gregoire, Lisa Berdan, MHS,† Ty Rorick, RN,† W. Schuyler Jones, MD,†
and Mark J. Pletcher, MD, MPH*‡
Background: Genuine patient engagement can improve research
relevance, impact and is required for studies using the National
Patient-Centered Clinical Research Network including major multi-
center research projects. It is unclear, however, how best to integrate
patients into governance of such projects.
Methods: ADAPTABLE (Aspirin Dosing: A Patient-centric Trial
Assessing Benefits and Long-term Effectiveness) is the first major
multicenter research project to be conducted in National Patient-Cen-
tered Clinical Research Network. Here, we provide a description of
how we implemented patient engagement in ADAPTABLE thus far,
including a description of committee structures and composition, first-
hand patient testimonials, specific contributions, and lessons learned
during the planning and early implementation of ADAPTABLE.
Results: We recruited 1 patient leader from 6 of the 7 enrolling
networks to serve on a Patient Review Board for ADAPTABLE,
supported the Board with an experienced patient engagement team
including an “investigator-advocate” not otherwise involved in the
trial, and facilitated bidirectional communication between the Board
and ADAPTABLE Coordinating Center. The Board has reviewed
and provided substantial input on the informed consent procedure,
recruitment materials, patient portal design, and study policy in-
cluding compensation of participants. Although it was “too late” for
some suggested modifications, most modifications suggested by the
patient leaders have been implemented, and they are enthusiastic
about the study and their role. The patient leaders also attend
Steering and Executive Committee calls; these experiences have
been somewhat less productive.
Conclusions: With adequate support, a cadre of committed patient
leaders can provide substantial value to design and implementation
of a major multicenter clinical trial.
Key Words: patient-centered Review Board, patient engagement,
ADAPTABLE, Adaptors
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Engaging patients as stakeholders in patient-centered com-parative effectiveness research is essential to answer questions
in research that are important to patients and caregivers.1–4
The Patient-Centered Outcomes Research Institute (PCORI) has
transformed the clinical research landscape by its institutional
commitment to funding only research projects with genuine patient
and stakeholder engagement.5 As a flagship PCORI project, the
National Patient-Centered Clinical Research Network (PCORnet)
is designed to leverage major patient partnerships and engage
patients meaningfully in all PCORnet research.
It is unclear, however, how patients will engage with major
multicenter research projects that PCORnet will enable. The
PCORI Methodology Report defines patient engagement including
defining research topics and formulating study questions; identi-
fying a study population and choosing interventions, comparators
and outcomes; developing optimal strategies for recruitment and
retention of study participants; conducting a study and analyzing
results; and disseminating research findings into clinical practice.6
Although, these activities are all relevant to major multicenter re-
search projects, the governance for these projects is already quite
complex, typically including a coordinating center, multiple clinical
sites, a Steering Committee (SC), an Executive Committee (EC), a
data and safety monitoring board, contractors, and often a sponsor
oversight body. How patients will fit into this governance structure,
interact with professional researchers and clinicians, and contribute
meaningfully in this context are open questions.
ADAPTABLE (Aspirin Dosing: A Patient-centric Trial
Assessing Benefits and Long-term Effectiveness) is a multicenter
pragmatic randomized controlled trial designed to compare the
effectiveness of 2 once-daily doses of aspirin for secondary pre-
vention in patients with atherosclerotic cardiovascular disease.4
ADAPTABLE will recruit 20,000 patients at high risk for is-
chemic events, randomize them (1:1) to receive an aspirin dose of
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81mg/d versus 325mg/d, and follow them for cardiovascular and
bleeding events over the course of 3 years.
Patient engagement has been carefully planned and
implemented throughout the trial, including constitution of a
Patient Review Board for the study comprised of “Adaptors,”
the patient leaders engaged to help lead ADAPTABLE. Here,
we provide a description of how we have implemented patient
engagement in ADAPTABLE thus far, including a descrip-
tion of committee structures and composition, first-hand
Adaptor testimonials, specific contributions of the Adaptors,
and lessons learned during the planning phases and early
implementation of ADAPTABLE.
METHODS
The Adaptors: A Patient Review Board for
ADAPTABLE Supported by the Health eHeart
Alliance
The Adaptors were envisioned as patient leaders who
would comprise a Patient Review Board for ADAPTABLE
tasked with watching over the study and ensuring that it re-
mained “patient centered.” Specifically, the Adaptors would
have roles in study planning, review of patient-facing materi-
als, recruitment support, and dissemination of study updates
and final results. By design, one Adaptor would be identified
from each of the 7 participating PCORnet Clinical Data Re-
search Networks (CDRNs) in order to represent patient view-
points from the geographic region of the participating sites and
to facilitate bidirectional communication between each net-
work, the Coordinating Center and SC. Adaptors are patients
that fit most, if not all, of the inclusion /exclusion criteria for
the study and are identified by a study site; we have 3 female
and 3 male Adaptors. One CDRN is still actively looking for a
patient leader. Each Adaptor would participate as a member of
the SC and also as a member of the Patient Review Board,
which would be hosted and supported by the Health eHeart
Alliance, a PCORnet Patient-Powered Research Network fo-
cused on cardiovascular health.7 Support for each Adaptor was
budgeted through the Health eHeart Alliance, which contracts
with Adaptors as consultants and supports travel and conven-
ing for trial activities.
An Interim Description of Process and Outcomes
With news of conditional approval by the PCORI Board
of Governors for ADAPTABLE in May 2015, the Duke Clin-
ical Research Institute (DCRI, lead institution for the ADAPT-
ABLE Coordinating Center) and the Health eHeart Alliance
initiated recruitment, orientation and engagement of the Adap-
tors identified from each participating CDRN. After one-on-one
training and onboarding calls were completed, official Adaptor
activities commenced on September 8, 2015 and are ongoing.
The Results below describe process and outcomes, organized by
Adaptor activity, through enrollment of the first ADAPTABLE
participant on April 19, 2016.
RESULTS
The Adaptor Patient Review Board
Conference Calls
The Adaptor Patient Review Board is comprised of the
Adaptors, Health eHeart Alliance leadership, and a liaison from
the Coordinating Center at DCRI. The Board convenes every
other week via conference call, hosted by the Health eHeart
Alliance, to discuss and provide input on study operations. The
Adaptors have found these calls to be engaging and productive
(Table 1, quotes 1–3). Below we describe some of the process
features of these conference calls.
Calls are facilitated by an experienced patient engage-
ment team that includes the Project Director and the Principal
TABLE 1. Testimonials to Adaptor Engagement
# Quoted Testimonial Role of Quoted Individual (N= 6)
1 “The teamwork is what made this special and so unique. This is not how this [research] has been done in the past.
We are patients across the country—on the line with doctors contributing, getting to collaborate and feel the
teamwork. We would negotiate and come together—different people have different thoughts and when you put
it all together it is special”
Adaptor
2 “The value of this for patients is immense—but when PATIENTS are saying this, this carries a different kind of
respect. This is respect that comes from the patient community. … the patients do not fully understand the
outcomes yet, but in a few years we will see them”. In a few years we can step back and one day we will say
“WOW this work was worth it!”
Adaptor
3 “Just [all of] us working together! Sometimes something would come to my mind (and as a patient you worry is
this right or wrong) but then another Adaptor will speak up—and we worked together for changes (even if they
are small) and overall we did some good work”
Adaptor
4 “... the [value] feels like it is getting lost in other calls, like the SC calls. There is a bit of an arrogance when
actually engaging the ADAPTORS. Need to be leveraging the PCORI message more to help bring people into
the network”
Adaptor
5 “This is the most exciting and interesting work I have ever done in multicenter trials—thanks to the Adaptors, we
see patients as our research partners not simply participants. We are learning together as we go forward and
implementing many of these ideas in other new trials”
DCRI Coordinating Center
representative
6 “While many around the country are talking about patient engagement in clinical trials, the ADAPTORS have
been truly involved in every aspect of the trial including study design, early implementation, and study guidance
at the Steering Committee level. While this has not been a smooth process (at times), I suspect that this will be a
model utilized many times in the future”
ADAPTABLE investigator
ADAPTABLE indicates Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness; DCRI, Duke Clinical Research Institute; PCORI, Patient-
Centered Outcomes Research Institute.
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Investigator of the Health eHeart Alliance. The Project Di-
rector provides a single point of contact for the Adaptors, and
a conduit of information from the Coordinating Center,
queues up items for discussion on the agendas, reports
Adaptor feedback back the Coordinating Center, and serves
as a bridge for the CDRN engagement teams. The Principal
Investigator, who is an experienced investigator, not other-
wise involved in ADAPTABLE, acts as an investigator-
advocate for the Adaptors and an unconflicted “translator”
between the patient and researcher perspectives.
We use a round-robin discussion format during each
call. Calls always start with “Check-Ins” where each partic-
ipant says what is on their mind as they settle into the call,
and end with “Check-Outs” where we capture any final
comments, questions, or concerns for discussion on the next
call. In addition, when discussing specific issues, we try to
repeat this round-robin format to give each Adaptor an ex-
plicit chance to provide input. An example of agenda topics
may include: reviewing PHI breach protocol, discussing
newsletter topics or reviewing CDRN recruitment materials.
Although these processes take time, they appear to be critical
for building trust and eliciting input.
The Adaptor Board does not use any video or web
conference software, and instead uses Google Docs as a
shared display and workspace during conference calls. The
online document, upon which the agenda is displayed and
notes are taken in real time (by all participants simulta-
neously, though primarily by Alliance staff), provides run-
ning documentation of discussions and decisions made by the
Adaptors. The notes are used by the Coordinating Center (the
link is stable over time) and distributed to CDRNs and con-
tractors as needed. This method appears to provide visual
support for the discussion with minimal technology overhead
for our Adaptors, while also facilitating transparent commu-
nications with the Coordinating Center.
SC and EC Participation
Along with participating on the Adaptor Patient Review
Board, all Adaptors are official members of the ADAPT-
ABLE SC and 2 Adaptors were elected to serve on the EC.
The SC group, comprised of the Adaptors, 3 investigators
from the Coordinating Center, 1-2 clinical investigators from
participating CDRNs, and 3 external advisors, has met by
conference call every other week through study startup. The
EC has convened once, mid-April with the patient leads, and
will continue to meet quarterly.
Although the Adaptors are welcomed and invited to
speak in this forum, they have felt less engaged. This is partly
due to the size of the SC, a meeting schedule that was not
always conducive of consistent Adaptor attendance, and the
topics were often of a clinical nature. Adaptors attending
those meetings, however, have also felt that their presence is
less valued in this forum (Table 1, quote 4), and they do not
speak up as frequently as in the Adaptor Board calls.
Adaptor Contributions to Study Policy and
Materials
Through their participation on the Adaptors Patient
Review Board and the SC, the Adaptors have been asked to
review various aspects of study policy and a variety of specific
patient-facing study materials. They have contributed both re-
actively as well as proactively, providing many specific sug-
gestions and also new unsolicited ideas about how to approach
and engage participants, via close review of ongoing Adaptor
meeting notes we were able to create Table 2, which provides a
partial listing of contributions to study policy and materials.
We continuously follow-up with the Coordinating Center to
assess if and how Adaptor feedback was utilized and report
back to our patient leaders; the majority of Adaptor suggestions
have been implemented by the Coordinating Center, though
some major suggestions have not (eg, celebrity videos and
some of the functionality of the portal, Table 2). Anecdotal
testimonials to Adaptor engagement utility from Coordinating
Center staff and investigators have been overwhelmingly
positive (Table 1, quotes 5-6). The Adaptors are now engaging
with the ADAPTABLE communications team to codesign a
website for the Adaptors that will describe their activities
and communicate how ADAPTABLE is engaging patients
“differently,” with the goal of inspiring positive participation in
ADAPTABLE from patients across the country.
DISCUSSION
The Adaptors provide an example of successful in-
tegration of patients into governance of a major multicenter
PCORnet research project. Although not all of their early
interactions with the study have been positive, they remain
inspired and productive, and have provided valuable con-
tributions especially to patient-relevant policy and patient-
facing study materials.
A number of lessons are evident from our experiences
to date. First, it is clear that patients can be most productive
when they are supported with dedicated sessions that can
be designed for positive patient engagement. In our expe-
rience, the large SC conference calls were not ideal in this
regard and did not yet yield substantial contributions from
patients. For future calls we suggest making sure there are
agenda items included that are patient focused as well as
reminders made to the leader of the call to actively include
the patient participants. In contrast, dedicated regular ses-
sions designed for patients appeared to be highly success-
ful. The key features of these dedicated sessions were: (1)
provision of a supportive forum for discussion and foster-
ing an atmosphere of mutual respect and self-efficacy; (2)
building the Adaptors’ research knowledge base and
keeping them informed of the trial progress; and (3)
bringing and framing relevant issues to the group, eliciting
Adaptor feedback, and delivering that feedback back to the
ADAPTABLE leadership team.
Second, it is best to start early with engagement and
provide opportunities for patients to have input at the for-
mative stage of study development. Several of the major new
ideas brought forward by the Adaptors were not implemented
because it appeared to be “too late” to do so. Although this
may be somewhat inevitable, we believe earlier engagement
would have ameliorated the issue and on subsequent projects
we are recommending that identification of a patient repre-
sentative be included as a contracted milestone.
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Third, we believe the Adaptors have benefited from
having a “critical mass” of patients. As implied by some of the
quoted testimony, the Adaptors encourage each other, and take
strength from shared discussions and coformulated ideas. Em-
ploying a single patient partner/leader or even 2-3 patients may
not be likely to produce the same type of shared strength and
focus group type dynamic that has proven to be effective in
this group.
In any case, ADAPTABLE is now launched, and the
Adaptors now enter a different phase of participation. Our role
in patient engagement will expand now to include designing and
disseminating study updates that we will send to the study
participants and also, we hope, to the broader patient com-
munity. It will be our goal to design a study update format that
will be patient friendly, engaging, and help support the ongoing
participation of patients over the 3 years of the trial. The Health
eHeart Alliance plans to leverage its own patient community as
well as its community forum to encourage dissemination of the
updates and conversation about the trial in general. How best to
design and support these study updates, and how frequently we
should produce them has yet to be decided, but we are com-
forted by the knowledge that we are working side-by-side in this
endeavor with a set of extraordinary and generous patient
leaders who are truly engaged and committed to the project.
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TABLE 2. Actionable Adaptor Feedback
Category of Input Specific Modifications Proposed
Implemented
(Y/N) Comments
Review
study
materi-
als
Informed consent Change the name of comprehension questions from “quiz” to
“review”
Y Participated in cognitive interview process
along with other patients to help shape the
development of the consent form
Shortening the consent review: combine 4 questions into 2, drop
2 questions
Y Patients felt there was some redundancy in the
original 4 questions and we were able to
shorten the review to 2 questions
Recruitment
letters
Language changes: specifically, shorter and simpler Y
Other recruitment
materials:
(flyers, emails)
Language changes, background color for screens as well as,
clearly pointing to location of study webpage
Y
Patient portal Language changes on: thank you page, study description, profile Y
Change welcome picture “Everyone looks unhappy…” Y
Portal color scheme—dark blue is easier to read Y
Add functionality allowing participants to leave portal and return
later to the same place in the consenting process on the
webpage
N Not able to save information or location before
consent
Add phone number, email, or code to follow-up with patients
who leave portal before consent: specifically, “can we find out
why they did not make it all the way through?”
N Not able to collect information for follow-up
before consent
The appropriate time/ place to collect SSN: “after onboarding,
only last 4, make it optional”
Y Adaptors gave study team confidence to collect
this piece of information!
Increase font size Y Adjusted length of document in order to
increase font size
Onboarding
process
Streamlined questions during onboarding Y
No: 0,1, O, L, or I’s in the “golden ticket” number for portal
entry
Y
Onboarding too long Y Removed medication modules to a subsequent
visit to shorten the onboarding/
randomization process
Study
poli-
cies
Compensation Allow participants to opt out of $25 compensation “donate to
research” option
Y Can opt out, but not able to donate $25
elsewhere
Trial publicity Language on the portal describing Adaptors Y
Promotional videos with celebrities, musicians, well known
community members
N Funding was limited and felt best to spend in
other areas
PSA highlighting Adaptable to larger community Y American Heart Association (AHA) will be
distributing patient-directed PSA in the local
CDRN communities
Adaptors page dedicated to the patient leaders Y In progress
Link from trial webpage to the Health eHeart Alliance forum for
broad community engagement
TBD
CDRN indicates Clinical Data Research Networks; N, no; PSA, Public Service Announcement; TBD, to be determined; Y, yes.
Faulkner et al Medical Care  Volume 56, Number 10 Suppl 1, October 2018
S14 | www.lww-medicalcare.com Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
REFERENCES
1. Hoffman A, Montgomery R, Aubry W, et al. How best to engage patients,
doctors, and other stakeholders in designing comparative effectiveness
studies. Health Aff (Millwood). 2010;29:1834–1841.
2. Concannon TW, Fuster M, Saunders T, et al. A systematic review of
stakeholder engagement in comparative effectiveness and patient-centered
outcomes research. J Gen Intern Med. 2014;29:1692–1701.
3. Concannon TW, Meissner P, Grunbaum JA, et al. A new taxonomy for
stakeholder engagement in patient-centered outcomes research. J Gen Intern
Med. 2012;27:985–991.
4. ADAPTABLE, the Aspirin Study-A Patient Centered Trial.
2016. Available at: http://theaspirinstudy.org/. Accessed May 10,
2016.
5. Selby JV, Beal AC, Frank L. The patient-centered outcomes research
institute (PCORI) national priorities for research and initial research
agenda. JAMA. 2012;307:1583–1584.
6. Hickam D. PCORI Methodology Report 2013, Patient Centered
Ourcomes Research Institute.
7. Health eHeart Alliance. 2015. Available at: http://health-eheartalliance.
org/. Accessed October 16, 2016.
Medical Care  Volume 56, Number 10 Suppl 1, October 2018 Patient Engagement in ADAPTABLE
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. www.lww-medicalcare.com | S15
